関連する実験動画
Updated: Sep 9, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
347
SURMOUNT-4では,トリゼパチドは肥満または体重過剰の成人の健康関連の生活の質の改善と関連している
Theresa Hunter Gibble1, Dachuang Cao1, Madhumita Murphy1
1Eli Lilly and Company, Indianapolis, Indiana, USA.
Obesity (Silver Spring, Md.)
|September 3, 2025
まとめ
ティルゼパチドの継続治療は,肥満患者の健康関連生活の質 (HRQoL) を維持した. 離脱は重量回復とHRQoLの悪化をもたらし,継続的な治療の重要性を強調した.
科学分野:
- 代謝障害と肥満に関する研究
- 内分泌学における臨床試験
- 臨床実務における患者報告結果の測定
背景:
- 肥満は慢性疾患で 長期的な治療が必要です
- ティルゼパチドは,以前の試験で体重を大幅に減少させました.
- SURMOUNT-4は,ティルゼパチドの長期的効果と離脱後の影響を調査した.
研究 の 目的:
- 健康に関する生活の質 (HRQoL) へのチルゼパチドの継続治療の影響を評価する.
- ティルゼパチドの持続治療とプラセボの間のHRQoLの変化を初期体重減少後に比較する.
- 体重変化とHRQoLの結果との関係を評価する.
主な方法:
- 670人の参加者が最大ティルゼパチド投与量を達成したランダム化対照試験 (SURMOUNT-4)
- 参加者は,ティルゼパチドを継続するか,プラセボを52週間服用するようにランダムに割り当てられました (W36- W88).
- HRQoLは,SF- 36v2,IWQOL- Lite- CT,EQ- 5D- 5Lを含む患者によるアウトカム (PROs) によって評価されました.
主要な成果:
- ティルゼパチドの継続治療は,PROの改善をW36からW88まで維持した.
- プラセボ群では,ティルゼパチドの投与中止後に体重回復に関連したPROの悪化が認められた.
- 体重の減少と身体的限界の増加は,数値的に大きなPRO改善と相関しています.
結論:
- ティルゼパチドの継続的な治療は,過体重または肥満の個体においてHRQoLの増加を維持します.
- ティルゼパチドの離脱はHRQoLの低下と体重の回復に関連しています.
- 肥満管理におけるHRQoLの長期的利益には,治療の継続が不可欠です.
関連する概念動画
Obesity
609
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
609
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
Drugs for Treatment of Constipation-Predominant IBS
326
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
326
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340

